Iwamoto N - Search Results

1

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.

Curti BD, Koguchi Y, Leidner RS, Rolig AS, Sturgill ER, Sun Z, Wu Y, Rajamanickam V, Bernard B, Hilgart-Martiszus I, Fountain CB, Morris G, Iwamoto N, Shimada T, Chang S, Traber PG, Zomer E, Horton JR, Shlevin H, Redmond WL. Curti BD, et al. Among authors: iwamoto n. J Immunother Cancer. 2021 Apr;9(4):e002371. doi: 10.1136/jitc-2021-002371. J Immunother Cancer. 2021. PMID: 33837055 Free PMC article. Clinical Trial.

2

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab.

Koguchi Y, Iwamoto N, Shimada T, Chang SC, Cha J, Curti BD, Urba WJ, Piening BD, Redmond WL. Koguchi Y, et al. Among authors: iwamoto n. J Immunother Cancer. 2021 Oct;9(10):e002663. doi: 10.1136/jitc-2021-002663. J Immunother Cancer. 2021. PMID: 34620702 Free PMC article.

3

Regulated LC-MS/MS bioanalysis technology for therapeutic antibodies and Fc-fusion proteins using structure-indicated approach.

Iwamoto N, Shimada T. Iwamoto N, et al. Drug Metab Pharmacokinet. 2019 Feb;34(1):19-24. doi: 10.1016/j.dmpk.2018.10.002. Epub 2018 Oct 19. Drug Metab Pharmacokinet. 2019. PMID: 30392772 Free article. Review.

4

Structure-Indicated LC-MS/MS Bioanalysis of Therapeutic Antibodies.

Iwamoto N, Shimada T. Iwamoto N, et al. Methods Mol Biol. 2022;2313:187-205. doi: 10.1007/978-1-0716-1450-1_11. Methods Mol Biol. 2022. PMID: 34478139

5

A rapid and universal liquid chromatograph-mass spectrometry-based platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics.

Iwamoto N, Koguchi Y, Yokoyama K, Hamada A, Yonezawa A, Piening BD, Tran E, Fox BA, Redmond WL, Shimada T. Iwamoto N, et al. Analyst. 2022 Sep 26;147(19):4275-4284. doi: 10.1039/d2an01032a. Analyst. 2022. PMID: 35997223

6

Recent advances in mass spectrometry-based approaches for proteomics and biologics: Great contribution for developing therapeutic antibodies.

Iwamoto N, Shimada T. Iwamoto N, et al. Pharmacol Ther. 2018 May;185:147-154. doi: 10.1016/j.pharmthera.2017.12.007. Epub 2017 Dec 22. Pharmacol Ther. 2018. PMID: 29274706 Free article. Review.

7

Acceleration of nano-surface and molecular-orientation limited (nSMOL) proteolysis with acidified reduction pretreatment for quantification of Tocilizumab.

Iwamoto N, Yonezawa A, Matsubara K, Shimada T. Iwamoto N, et al. J Pharm Biomed Anal. 2019 Feb 5;164:467-474. doi: 10.1016/j.jpba.2018.11.019. Epub 2018 Nov 8. J Pharm Biomed Anal. 2019. PMID: 30447535

8

Comparison of Bevacizumab Quantification Results in Plasma of Non-small Cell Lung Cancer Patients Using Bioanalytical Techniques Between LC-MS/MS, ELISA, and Microfluidic-based Immunoassay.

Iwamoto N, Takanashi M, Shimada T, Sasaki J, Hamada A. Iwamoto N, et al. AAPS J. 2019 Aug 20;21(6):101. doi: 10.1208/s12248-019-0369-z. AAPS J. 2019. PMID: 31432293

9

Validated LC/MS Bioanalysis of Rituximab CDR Peptides Using Nano-surface and Molecular-Orientation Limited (nSMOL) Proteolysis.

Iwamoto N, Takanashi M, Hamada A, Shimada T. Iwamoto N, et al. Biol Pharm Bull. 2016 Jul 1;39(7):1187-94. doi: 10.1248/bpb.b16-00230. Epub 2016 Apr 28. Biol Pharm Bull. 2016. PMID: 27150271 Free article.

10

Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis.

Iwamoto N, Hamada A, Shimada T. Iwamoto N, et al. Anal Biochem. 2018 Jan 1;540-541:30-37. doi: 10.1016/j.ab.2017.11.002. Epub 2017 Nov 9. Anal Biochem. 2018. PMID: 29128290 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

621 results

Search Page